612 related articles for article (PubMed ID: 19301821)
1. Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
Colotta V; Lenzi O; Catarzi D; Varano F; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Traini C; Pedata F; Morizzo E; Moro S
J Med Chem; 2009 Apr; 52(8):2407-19. PubMed ID: 19301821
[TBL] [Abstract][Full Text] [Related]
2. New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
Colotta V; Catarzi D; Varano F; Capelli F; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Pedata F; Schiesaro A; Morizzo E; Moro S
J Med Chem; 2007 Aug; 50(17):4061-74. PubMed ID: 17665891
[TBL] [Abstract][Full Text] [Related]
3. 1,2,4-triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies.
Colotta V; Catarzi D; Varano F; Calabri FR; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Deflorian F; Moro S
J Med Chem; 2004 Jul; 47(14):3580-90. PubMed ID: 15214785
[TBL] [Abstract][Full Text] [Related]
4. The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition.
Cheong SL; Dolzhenko A; Kachler S; Paoletta S; Federico S; Cacciari B; Dolzhenko A; Klotz KN; Moro S; Spalluto G; Pastorin G
J Med Chem; 2010 Apr; 53(8):3361-75. PubMed ID: 20307065
[TBL] [Abstract][Full Text] [Related]
5. 4-amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
Lenzi O; Colotta V; Catarzi D; Varano F; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Varani K; Marighetti F; Morizzo E; Moro S
J Med Chem; 2006 Jun; 49(13):3916-25. PubMed ID: 16789747
[TBL] [Abstract][Full Text] [Related]
6. 1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological evaluation, and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives.
Catarzi D; Colotta V; Varano F; Lenzi O; Filacchioni G; Trincavelli L; Martini C; Montopoli C; Moro S
J Med Chem; 2005 Dec; 48(25):7932-45. PubMed ID: 16335918
[TBL] [Abstract][Full Text] [Related]
7. 5-amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: a versatile scaffold to obtain potent and selective A3 adenosine receptor antagonists.
Da Settimo F; Primofiore G; Taliani S; Marini AM; La Motta C; Simorini F; Salerno S; Sergianni V; Tuccinardi T; Martinelli A; Cosimelli B; Greco G; Novellino E; Ciampi O; Trincavelli ML; Martini C
J Med Chem; 2007 Nov; 50(23):5676-84. PubMed ID: 17927167
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, ligand-receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonists.
Colotta V; Catarzi D; Varano F; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Traini C; Pugliese AM; Pedata F; Morizzo E; Moro S
Bioorg Med Chem; 2008 Jun; 16(11):6086-102. PubMed ID: 18468446
[TBL] [Abstract][Full Text] [Related]
9. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation.
Pastorin G; Da Ros T; Spalluto G; Deflorian F; Moro S; Cacciari B; Baraldi PG; Gessi S; Varani K; Borea PA
J Med Chem; 2003 Sep; 46(20):4287-96. PubMed ID: 13678407
[TBL] [Abstract][Full Text] [Related]
10. New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists.
Baraldi PG; Tabrizi MA; Preti D; Bovero A; Fruttarolo F; Romagnoli R; Zaid NA; Moorman AR; Varani K; Borea PA
J Med Chem; 2005 Jul; 48(15):5001-8. PubMed ID: 16033279
[TBL] [Abstract][Full Text] [Related]
11. Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine skeleton as a key study.
Morizzo E; Capelli F; Lenzi O; Catarzi D; Varano F; Filacchioni G; Vincenzi F; Varani K; Borea PA; Colotta V; Moro S
J Med Chem; 2007 Dec; 50(26):6596-606. PubMed ID: 18047262
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists.
Baraldi PG; Tabrizi MA; Preti D; Bovero A; Romagnoli R; Fruttarolo F; Zaid NA; Moorman AR; Varani K; Gessi S; Merighi S; Borea PA
J Med Chem; 2004 Mar; 47(6):1434-47. PubMed ID: 14998332
[TBL] [Abstract][Full Text] [Related]
13. Substituted pyrazolo[3,4-b]pyridines as potent A1 adenosine antagonists: synthesis, biological evaluation, and development of an A1 bovine receptor model.
Tuccinardi T; Schenone S; Bondavalli F; Brullo C; Bruno O; Mosti L; Zizzari AT; Tintori C; Manetti F; Ciampi O; Trincavelli ML; Martini C; Martinelli A; Botta M
ChemMedChem; 2008 Jun; 3(6):898-913. PubMed ID: 18338422
[TBL] [Abstract][Full Text] [Related]
14. 2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition.
Lenzi O; Colotta V; Catarzi D; Varano F; Poli D; Filacchioni G; Varani K; Vincenzi F; Borea PA; Paoletta S; Morizzo E; Moro S
J Med Chem; 2009 Dec; 52(23):7640-52. PubMed ID: 19743865
[TBL] [Abstract][Full Text] [Related]
15. Selective human adenosine A3 antagonists based on pyrido[2,1-f]purine-2,4-diones: novel features of hA3 antagonist binding.
Priego EM; Pérez-Pérez MJ; von Frijtag Drabbe Kuenzel JK; de Vries H; Ijzerman AP; Camarasa MJ; Martín-Santamaría S
ChemMedChem; 2008 Jan; 3(1):111-9. PubMed ID: 18000937
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and pharmacological evaluation of novel octahydro-1H-pyrido[1,2-a]pyrazine as mu-opioid receptor antagonists.
Le Bourdonnec B; Goodman AJ; Graczyk TM; Belanger S; Seida PR; DeHaven RN; Dolle RE
J Med Chem; 2006 Dec; 49(25):7290-306. PubMed ID: 17149859
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations.
Pastorin G; Da Ros T; Bolcato C; Montopoli C; Moro S; Cacciari B; Baraldi PG; Varani K; Borea PA; Spalluto G
J Med Chem; 2006 Mar; 49(5):1720-9. PubMed ID: 16509587
[TBL] [Abstract][Full Text] [Related]
18. Does the combination of optimal substitutions at the C²-, N⁵- and N⁸-positions of the pyrazolo-triazolo-pyrimidine scaffold guarantee selective modulation of the human A₃ adenosine receptors?
Cheong SL; Dolzhenko AV; Paoletta S; Lee EP; Kachler S; Federico S; Klotz KN; Dolzhenko AV; Spalluto G; Moro S; Pastorin G
Bioorg Med Chem; 2011 Oct; 19(20):6120-34. PubMed ID: 21908194
[TBL] [Abstract][Full Text] [Related]
19. [(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors.
Varani K; Merighi S; Gessi S; Klotz KN; Leung E; Baraldi PG; Cacciari B; Romagnoli R; Spalluto G; Borea PA
Mol Pharmacol; 2000 May; 57(5):968-75. PubMed ID: 10779381
[TBL] [Abstract][Full Text] [Related]
20. A novel class of adenosine A3 receptor ligands. 2. Structure affinity profile of a series of isoquinoline and quinazoline compounds.
van Muijlwijk-Koezen JE; Timmerman H; Link R; van der Goot H; Ijzerman AP
J Med Chem; 1998 Oct; 41(21):3994-4000. PubMed ID: 9767637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
